 | | Vol. 15.01 – 12 January, 2024 |
| |
|
|
| Researchers developed a targeted DNA methylation assay to detect castration-resistant neuroendocrine prostate cancer (CRPC-NE) using plasma cell-free DNA, which quantified tumor content and provided a phenotype evidence score that captured diverse CRPC phenotypes.
[Cancer Discovery] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists employed single-cell RNA sequencing to delineate molecular changes in tumor stroma that influence prostate cancer progression and metastasis.
[Nature Communications] |
|
|
|
| CCK8 assay and colony formation assay were used to illustrate the key role of AGPS in the progression of prostate cancer in vitro.
[Journal Of Experimental & Clinical Cancer Research] |
|
|
|
| The authors used RNAseq, chromatin immunoprecipitation, and biostatistics analyses to suggest the molecular mechanisms explaining the role of ALDH1A1 in prostate cancer progression.
[Theranostics] |
|
|
|
| The impact of 2,4-dienoyl CoA reductase 2 (DECR2) and peroxisomal β-oxidation inhibition via thioridazine was examined in vitro, in vivo, and in clinical prostate tumours cultured ex vivo.
[British Journal of Cancer] |
|
|
|
| Researchers examined methylation patterns and GE in prostate cancer patients by using a novel tumor deconvolution approach to identify and correct for cell-type proportions of the tumor microenvironment in its epigenome-wide association study and differential expression analysis.
[Clinical Epigenetics] |
|
|
|
| Combined inhibition of heat shock factor 1 and cystathionine-β-synthase resulted in more pronounced inhibition of prostate cancer cell proliferation and reduction of transsulfuration pathway metabolites.
[Communications Biology] |
|
|
|
| Genomic classifiers provide a small but consistent improvement upon the prognostic ability of clinical classification schemes, which may be helpful when treatment decisions are uncertain.
[Prostate Cancer And Prostatic Diseases] |
|
|
|
| To investigate the role of serine/threonine kinase 36 on cell proliferation, invasion, and migration, serine/threonine kinase 36 was overexpressed and silenced in DU-145 and PC-3 cell lines.
[Scientific Reports] |
|  |
|
|
|
| The authors review the role of different molecular determinants of prostate cancer progression to lethal disease including the phenotypic dynamic of cell plasticity, EMT-MET interconversion, and signaling-pathways driving prostate cancer cells to advance and metastasize.
[Expert Opinion On Therapeutic Targets] |
|
|
|
|
| Merck announced the initiation of pivotal Phase III trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors.
[Merck] |
|
|
|
|
| March 18 – 19, 2024
London, England, United Kingdom |
|
|
|
|
|
| | The Vancouver Prostate Centre – Vancouver, British Columbia, Canada |
|
|
|
| | Human Technopole – Milan, Italy |
|
|
|
| | Jefferson-Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States |
|
|
|
| | MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | Pfizer – Multiple Locations, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
